A Study to Compare 2 Formulations of LY900014 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The study involves a comparison of a LY900014 U-200 formulation with a LY900014 U-100 formulation. LY900014 is a type of fast acting insulin. Study participants will be administered LY900014 U-100 two times and LY900014 U-200 two times, over 4 study periods, by injection under the skin. Blood samples will be taken to compare how the body handles the study drugs and how they affect the blood sugar levels. Side effects and tolerability will be documented. The study will last about 4 weeks, not including screening and follow up. Screening is required within 28 days prior to the start of the study and follow up is required at least 2 weeks after the last dose of study drug.

Official Title
-----------------
Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY900014 U-200 Formulation With LY900014 U-100 Formulation in Healthy Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: LY900014-U200
* Drug: LY900014-U100


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion) Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²) Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study Have veins suitable for easy blood collection and glucose solution infusion Exclusion Criteria: Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study Have previously participated or withdrawn from this study Had blood loss of more than 450 milliliters (mL) within the last 3 months Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female) Smoke more than 10 cigarettes per day Are infected with hepatitis B or human immunodeficiency virus (HIV) Are taking illegal drugs

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY900014-U200<br>Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods | Drug: LY900014-U200<br>* Administered SC<br>* Other names: Ultra-Rapid Lispro;|
| Experimental: LY900014-U100<br>Single SC dose of 15 U LY900014 U-100 in two of four study periods | Drug: LY900014-U100<br>* Administered SC<br>* Other names: Ultra-Rapid Lispro;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK): Insulin Lispro Area Under Plasma Concentration Curve Zero to 10 Hours (AUC[0-10]) | Insulin Lispro AUC From Time Zero to 10 hours post dose (AUC[0-10h]) | Predose, 5 minutes (mn), 10mn, 15mn, 20mn, 25mn, 30mn, 35mn, 40mn, 45 mn, 50mn, 55 mn, 60mn, 70mn,90mn,120mn,150mn,180mn, 240mn,300mn,360mn,320mn, 480mn, 540mn, and 600mn (10 hours) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacodynamics (PD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp for Each Treatment Arm | Glucodynamics: Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure. | Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose |